IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

NOVARTIS PHARMACEUTICALS CORPORATION, NOVARTIS AG, NOVARTIS PHARMA AG, NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. and LTS LOHMANN THERAPIE-SYSTEME AG. C.A. No. 13-cv-52-RGA Plaintiffs, (consolidated) v. ALVOGEN PINE BROOK, INC. and ALVOGEN GROUP, INC., Defendants. X X NOVARTIS PHARMACEUTICALS CORPORATION, NOVARTIS AG, NOVARTIS PHARMA AG, NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. and LTS LOHMANN THERAPIE-SYSTEME AG, Plaintiffs, C.A. No. 13-cv-527-RGA v. NOVEN PHARMACEUTICALS, INC., Defendant.

PROPOSEDI ORDER

WHEREAS the Court has considered the arguments set forth in the parties' March 14, 2014 joint claim construction briefs and appendix (13-cv-52-RGA, D.I. 132, 133; 13-cv-527-RGA, D.I. 88, 89), and the oral argument heard at the Markman hearing held on April 3, 2014 in the above-captioned cases;

IT IS HEREBY ORDERED that, for the reasons expressed by the Court at the April 3, 2013 Markman hearing in the above-captioned cases, the Court hereby construes the following claim terms in U.S. Patents Nos. 6,335,031 and 6,316,023 as set forth below:

Claim Term	Court's Construction
antioxidant	agent(s) that reduce(s) oxidative degradation (presence only)
about 0.01 to about 0.5 percent by weight	about 0.01 to about 0.5 percent by weight
diluent or carrier	inactive ingredient(s) of the pharmaceutical composition that aid(s) in the administration of the drug (presence only)
a/the composition (in claims 15 and 18, respectively, of the '031 Patent)	a/the composition
an amount of antioxidant effective to stabilize Compound A from degradation	an amount of antioxidant that will significantly reduce the degradation of Compound A over a prolonged period of time
stabilizing	significantly reducing degradation over a prolonged period of time

__, 2014.

Jnited States District Court Judge